Apollo Hospitals, Max Healthcare shares jump after Macquarie turns from bear to bull
The brokerage skipped 'neutral' and moved both hospital chains straight from Underperform to Outperform, sharply raising its price targets. Apollo hit a fresh high and ended as the Nifty's best performer on Friday.
It is not every day that a brokerage changes its mind this completely. On Friday, Macquarie upgraded Apollo Hospitals and Max Healthcare from 'Underperform' to 'Outperform', jumping two notches and skipping 'Neutral' altogether, according to Univest and Business Today. Apollo Hospitals shares hit a fresh high, and both stocks ended among the day's biggest gainers.
In plain words, Macquarie had been telling its clients that these two stocks would probably do worse than the market. Now it says they will probably do better. The size of the price targets shows how far the view has moved. Macquarie lifted its target for Apollo Hospitals to ₹10,500 from ₹6,230, and for Max Healthcare to ₹1,450 from ₹825, Business Today and Univest reported. A price target is simply a brokerage's estimate of where a share could trade in about a year. It is an opinion, not a promise.
Business Today worked out the implied upside at about 20% for Apollo and about 37% for Max. Univest, using midday prices, put it closer to 14% and 34%, because the shares had already risen by then. NewsBytes said Macquarie sees Max as offering the better balance of risk and reward of the two.
Why the change of heart? According to NewsBytes and Univest, Macquarie believes earnings at both chains have stabilised after a period of uneven growth. It also expects the many new hospital beds the companies have added to fill up better, and it thinks worries about the cost of that expansion are already reflected in the share prices. Valuations, it says, now look more reasonable.
The market liked the call. Apollo Hospitals closed 5.17% higher, the best performer in the Nifty 50, and Max Healthcare rose 3.74%, according to Marketcalls' post-market report. Apollo hit a fresh high during the day: Univest put it at ₹9,245 by about 12:40 pm. Univest reported that other hospital stocks rose too, with Narayana Hrudayalaya up about 4.4% at midday, and that the BSE Hospitals index rose roughly 3%.
It has been a bumpy month for the sector. Hospital stocks rebounded on 16 November after a sell-off driven by worries about possible government action on healthcare pricing, Kotak Neo reported. Those worries were linked to Supreme Court questions in September about medicine markups and hospitals making patients buy medicines from in-house pharmacies.
Not everything in the numbers is rosy. In the September quarter, Apollo's revenue grew 22.7% and its net profit rose 33.5% from a year earlier, but Max's net profit fell 15.6% even though its revenue grew 20.4%, according to Univest. Both stocks are also expensive by usual measures. Univest said Apollo trades at about 56 times its past year's earnings and Max at about 75 times. Business Today listed the key risks as drug price caps, the mix of institutional patients, such as those referred under insurance or government schemes, and rising operating costs.
What next? Brokerage calls can move a stock for a day or two, but over time prices follow results. The next real test for both companies will be their December-quarter numbers, along with any move by regulators on hospital and medicine pricing.
Get the day's best stories on WhatsApp. Free, a few a day, no spam.
Follow on WhatsAppSource ledger · स्रोत खाता
Each fact in this story, where it came from, and how it was checked.
| Fact | Source | Check |
|---|---|---|
| Macquarie upgraded both from Underperform to Outperform (two notches); old and new targets; implied upside about 14% (Apollo) and 34% (Max) at midday prices; reasons (earnings stabilising, new-bed utilisation, valuation); midday moves incl. Narayana Hrudayalaya +4.43% | Univest (Neeraj Pandey) | Confirmed, independent outlets |
| Upgrade to Outperform from Underperform; Max target ₹1,450 from ₹825 (about 37% upside); Apollo target ₹10,500 from ₹6,230 (about 20% upside); Apollo all-time high ₹9,089; risks: drug price caps, institutional patient mix, rising operating costs | Business Today (BT TV) | Confirmed, independent outlets |
| Upgrade to Outperform; targets ₹1,450 and ₹10,500; reasons including that new-bed concerns are priced in and valuations are more attractive; Max preferred on risk-reward | NewsBytes | Confirmed, independent outlets |
| Closing moves: Apollo Hospitals +5.17% (top Nifty gainer), Max Healthcare +3.74%; rally after Macquarie upgrade | Marketcalls post-market report | Single source |
| Apollo Hospitals and Max Healthcare among top Nifty gainers (names only) | Kotak Neo closing bell | Confirmed, independent outlets |
| BSE Hospitals index up about 3%; Q2 results (Apollo revenue +22.7%, profit +33.5%; Max revenue +20.4%, profit -15.6%); valuations about 56x and 75x trailing earnings | Univest | Single source |
| 16 Nov sell-off and rebound in hospital stocks over regulatory pricing worries; Supreme Court's September questions on medicine markup and in-house pharmacies | Kotak Neo | Single source |
Corrections to this story: none.